

Freedom of Information Request: Our Reference CTMUHB_359_23

Please see provided below tables populated with data that is currently available to Medicines Management. The period the data relates to is noted in the relevant table.

The data comprises of medicines specifically issued to the specialty of Dermatology. Unfortunately, where medicines have been prescribed by Dermatology but have been issued to wards/clinics in these circumstances our systems are not able to identify individual specialties. Therefore, there may be data that has been unavoidable omitted.

Where the patient numbers are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q1. How many patients were treated in the last 4 months (April to July 2023) by the dermatology department with each of the following products:

- **Abrocitinib**
- **Acitretin**
- **Alitretinoin**
- **Azathioprine**
- **Baricitinib**
- **Ciclosporin**
- **Dupilumab**
- **Methotrexate**
- **Mycophenolate mofetil**
- **Pimecrolimus**
- **Tacrolimus ointment**
- **Tralokinumab**
- **Upadacitinib**
- **Phototherapy (UVB or PUVA)**

We are only able to provide data in the format of patient numbers for those medicines listed in table 1a. The medicines in table 1b can only be supplied in the format of number of issues and this is due to the way the data is recorded in our systems.

The detailed patient information you require for the treatments in 1b would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and

significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

1a

	Patient Numbers
Medicine	April 23 to July 23
Abrocitinib	5
Baricitinib	10
Dupilumab (Dupixant)	141
Tralokinumab	7
Upadacitinib	14
Phototherapy (UVB or PUVA)	72

1b

	Issues	
Medicine	Pack size	April 23 to July 23
Acitretin	1x60 Capsules	361
Alitretinoin	1x30 Capsules	22
Azathioprine	1x28 Tablet	5
Azathioprine	1x56 Tablet	25
Azathioprine	50 mg in 5mL Oral Liquid	6
Ciclosporin	1x30 tablets	98
Ciclosporin	50 mL Bottle	0
Ciclosporin	150 mL Bottle	8
Methotrexate (pre-filled pens)	1 Pre-Filled Pen Pack	256
Methotrexate	24 Tablet Pack	150
Mycophenolate mofetil	50 Tablet Pack	23
Mycophenolate mofetil	100 Tablet Pack	0
Pimecrolimus		0
Tacrolimus ointment	30 g Pack	4
Tacrolimus ointment	60 g Pack	2

Q2. How many patients were treated by the dermatology department in the previous 4-month period (December 22 - March 23) with Dupixent?

Medicine	December 22 to March 23	April 23 to July 23	Number of Patient treated December 22 to March 23 and April 23 to July 23
Dupilumab (Dupixant)	135	141	120

Q3. For patients treated by the dermatology department with Dupilumab in the four months from December 22 to March 2023, could you please tell us:

- a. How many patients were treated in the subsequent 4-month period (April - July 23) with Dupilumab?**

Please see response provided in the table to question 2.

- b. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following advanced therapies - Abrocitinib, Baricitinib, Tralokinumab and Upadacitinib?**

Number of patients that were treated in the subsequent 4-month period (April - July 23) with any of the following advanced therapies:

Medicine	Number of Patients
Abrocitinib	0
Baricitinib	0
Tralokinumab	0
Upadacitinib	**

- c. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following immunosuppressants - Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?**
- d. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following - Acitretin, Alitretin, Pimecrolimus or Tacrolimus?**

Unfortunately, we are unable to provide information requested due to the way the data is recorded in our systems.

The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the

18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.